Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease.
about
Rivastigmine for Alzheimer's diseaseRivastigmine for Alzheimer's diseaseRivastigmine for Alzheimer's diseaseDesigning Second Generation Anti-Alzheimer Compounds as Inhibitors of Human Acetylcholinesterase: Computational Screening of Synthetic Molecules and Dietary PhytochemicalsAdverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and CanadaGypsogenin derivatives: an unexpected class of inhibitors of cholinesterases.Brief review: rivastigmine, a second cholinesterase inhibitor.Development and validation of a HPLC method for quantification of rivastigmine in rat urine and identification of a novel metabolite in urine by LC-MS/MS.Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions.Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders.Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease.Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activitiesCholinergic circuits and signaling in the pathophysiology of schizophreniaNeuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.A Randomized, Crossover, Single-Dose Bioequivalence Study of Two Extended-Release Tablets of Donepezil 23 mg in Healthy Human Volunteers under Fasting and Fed States.Rivastigmine in Parkinson's disease dementia.Rivastigmine in Parkinson's disease dementia.Design and Synthesis of New Dual Binding Site Cholinesterase Inhibitors: in vitro Inhibition Studies with in silico DockingRivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.Potential of bone marrow mesenchymal stem cells in management of Alzheimer's disease in female rats.Computational analysis of novel drugs designed for use as acetylcholinesterase inhibitors and histamine H3 receptor antagonists for Alzheimer's disease by docking, scoring and de novo evolution.Synthesis and biological evaluation of tacrine-thiadiazolidinone hybrids as dual acetylcholinesterase inhibitors.Achiral bis-imine in combination with CoCl₂: A remarkable effect on enantioselectivity of lipase-mediated acetylation of racemic secondary alcoholHigh-performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies.Cholinergic agonism alters cognitive processing and enhances brain functional connectivity in patients with multiple sclerosis.Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch.Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects.In vitro inhibitory profile of NDGA against AChE and its in silico structural modifications based on ADME profile.Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats.An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine.An Efficient Synthesis of bi-Aryl Pyrimidine Heterocycles: Potential New Drug Candidates to Treat Alzheimer's Disease.Acetylcholinesterase treatment--modelling potential demand and auditing practice.
P2860
Q24186551-7A4297FD-F2CE-4A91-A337-BABC018E78C1Q24187067-A0AA8B06-94BD-4113-B07B-988834045342Q24241686-6D607237-6852-46F2-BA89-9EA2B8F58243Q28547651-CBF8F42B-8E24-40C0-856C-0150FE6CA658Q28551402-3FE5E324-FB6D-4773-A571-26B27672AB75Q30317236-A07AF9AE-C958-47DC-9494-4A0F6C16BB58Q32122268-C395A2A2-27EE-4C46-BF73-2233D557F164Q33601656-D2914F28-1AF1-4F11-B5D4-ECC58FA0B76EQ34171486-EFC11D2C-6BD9-4F71-92AC-76D4FCE7D1F0Q34240980-61BAED97-D082-4FFA-AD2F-0FA05A181A71Q34327769-6E2D4019-D7B9-47F8-88E6-223DFB34ED9CQ35560078-D19FD7F2-3575-48F5-AD31-684BC08AC2EDQ36012323-34C0FF34-F536-40E2-A76A-75630A9B659CQ36756379-B7ADFF76-DEE9-4D75-B24A-08CC9FD7F3AFQ37005143-C1AC1B7F-4B8D-4DE8-B8DC-A831CF546C05Q37218956-7315FFC0-B694-4707-9DC1-82B2C09AF74AQ37232006-9B868B0B-FE55-40D2-9960-825AB8DD220DQ37556550-D545BE06-D572-41AA-8995-9F34FD484881Q37688131-9D999327-00BA-4F39-A9DA-5A876622A464Q37895257-27F1671C-9E37-4C49-9FB4-BFDA4270F037Q38225721-F31848E1-DEE7-442E-99C3-B360267EAA78Q39203644-ECA3BDC2-AF15-4193-BC05-7B1F270CA643Q39252940-98F81713-CB7E-4F84-BF68-DA0D2FDBB6B4Q40464743-BF98EE91-8DF3-4D0E-8E26-62941DA07ED3Q41156793-735897C4-C446-43A7-993B-64AA8FACCCD2Q41843713-673ACD6E-FE0B-4A49-9A6B-494E59DC89BEQ44095984-B2EA0B84-3063-435A-8183-871A4E76B20CQ46107336-7DF7E885-6138-40D1-BB8E-09475A871C29Q46804778-2DA08445-E4C9-4E53-AB89-D93E6CE9979AQ48258202-B942E532-30A9-4989-A5D8-0341111EFFC8Q48440891-B8A0DFE3-1914-4AEE-9582-01EBAFB43890Q50328399-6AB19C56-FFC2-42FF-AAA3-62CEADC84965Q50881585-10DF20CB-F5F2-43B6-998B-64A5B8915BB8Q51961414-91FEDF72-99B9-44BD-BEDC-0E69D69DD36D
P2860
Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Rivastigmine, a new-generation ...... atment of Alzheimer's disease.
@ast
Rivastigmine, a new-generation ...... atment of Alzheimer's disease.
@en
type
label
Rivastigmine, a new-generation ...... atment of Alzheimer's disease.
@ast
Rivastigmine, a new-generation ...... atment of Alzheimer's disease.
@en
prefLabel
Rivastigmine, a new-generation ...... atment of Alzheimer's disease.
@ast
Rivastigmine, a new-generation ...... atment of Alzheimer's disease.
@en
P2860
P1433
P1476
Rivastigmine, a new-generation ...... atment of Alzheimer's disease.
@en
P2093
P2860
P356
10.1592/PHCO.20.1.1.34664
P407
P577
2000-01-01T00:00:00Z